



Hereditary Cancer Genes & Diseases¹⁻⁶²

Gene	Breast	Ovarian	Endometrial (Uterine)	Colorectal	Stomach (Gastric)	Prostate	Pancreatic	Other	NCCN Guidelines for Testing ¹
APC				✓	✓		✓	✓	✓
ATM	✓					✓	✓		✓
BARD1	✓								✓
BMPR1A				✓	✓		✓	✓	✓
BRCA1	✓	✓				✓	✓	✓	✓
BRCA2	✓	✓				✓	✓	✓	✓
BRIP1	✓	✓				✓			✓
CDH1	✓			✓	✓				✓
CDKN2A							✓	✓	
CHEK2	✓			✓		✓		✓	✓
EPCAM		✓	✓	✓	✓	✓	✓	✓	✓
FH								✓	
FLCN								✓	
MLH1		✓	✓	✓	✓	✓	✓	✓	✓
MRE11A	✓	✓							
MSH2		✓	✓	✓	✓	✓	✓	✓	✓
MSH6		✓	✓	✓	✓	✓	✓	✓	✓
MUTYH	✓		✓	✓	✓				✓
NBN	✓					✓		✓	✓
PALB2	✓					✓	✓		✓
PMS2		✓	✓	✓	✓	✓	✓	✓	✓
PTEN	✓		✓	✓				✓	✓
RAD50	✓	✓							
RAD51C		✓				✓			✓
RAD51D		✓				✓			✓
RINT1	✓		✓	✓					
SDHB					✓			✓	
SMAD4				✓	✓		✓	✓	✓
STK11	✓	✓	✓	✓	✓		✓	✓	✓
TP53	✓	✓	✓	✓	✓	✓	✓	✓	✓
VHL							✓	✓	✓
XRCC2	✓								

Note: For genes not included in NCCN guidelines, these gene / disease relationships are supported by evidence from peer reviewed reports of research conducted in humans.

References

1. National Comprehensive Cancer Network clinical practice guidelines in oncology (NCCN Guidelines®). Genetic/Familial High-Risk Assessment: Colorectal; Genetic/Familial High-Risk Assessment: Breast and Ovarian; NCCN Clinical Practice Guidelines: Kidney Cancer <http://www.nccn.org>
2. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet.* 2003;72:1117-1130.
3. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. *J Clin Oncol.* 2007;25:1329-1333.
4. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med.* 1997;336:1401-1408.
5. Tai YC, Domchek S, Parmigiani G, et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J Natl Cancer Inst.* 2007;99:1811-1814.
6. Thompson D, Easton DF, Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. *J Natl Cancer Inst.* 2002;94:1358-1365.
7. Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst.* 1999;91:1310-1316.
8. Kote-Jarai Z, Leongamornlert D, Saunders E, et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. *Br J Cancer.* 2011;105:1230-1234.
9. Thompson D, Easton D, Breast Cancer Linkage C. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. *Am J Hum Genet.* 2001;68:410-419.
10. Fitzgerald RC, Hardwick R, Huntsman D, et al. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. *J Med Genet.* 2010;47:436-444.
11. Hansford S, Kaurah P, Li-Chang H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. *JAMA Oncol.* 2015;1:23-32.
12. Bubián V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J Med Genet.* 2013;50:255-263.
13. Pilarski R, Stephens JA, Noss R, et al. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome clinical features. *J Med Genet.* 2011;48:505-512.
14. Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res.* 2012;18:400-407.
15. Schneider K, Zellek K, Nichols KE, Garber J. Li-Fraumeni syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. *GeneReviews®* [Internet]. Seattle, WA; Copyright, University of Washington, Seattle; 1993-2016. <http://www.ncbi.nlm.nih.gov/books/NBK1311/>. Updated April 11, 2013. Accessed May 17, 2016.
16. Cybulski C, Kluzniak W, Huzarski T, et al. Clinical outcomes in women with breast cancer and a PALB2 mutation: a prospective cohort analysis. *Lancet Oncol.* 2015;16:638-644.
17. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. *Science.* 2009;324:217.
18. Goldgar DE, Healey S, Dowty JG, et al. Rare variants in the ATM gene and risk of breast cancer. *Breast Cancer Res.* 2011;13:R73.
19. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. *Cancer Discov.* 2012;2:41-46.
20. Thompson D, Duedal S, Kirner J, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. *J Natl Cancer Inst.* 2005;97:813-822.
21. Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. *J Clin Oncol.* 2011;29:3747-3752.
22. Cybulski C, Wokolorczyk D, Kluzniak W, et al. An inherited NBN mutation is associated with poor prognosis prostate cancer. *Br J Cancer.* 2013;108:461-468.
23. Naslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen General Population Study. *J Clin Oncol.* 2016;34:1208-1216.
24. Xiang HP, Geng XP, Ge WW, et al. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. *Eur J Cancer.* 2011;47:2546-2551.
25. Kohlmann W, Gruber SB. Lynch syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. *GeneReviews®* [Internet]. Seattle, WA; Copyright, University of Washington, Seattle; 1993-2016. <http://www.ncbi.nlm.nih.gov/books/NBK1211/>. Updated May 22, 2014. Accessed June 20, 2016.
26. Kempers MJ, Kuiper RP, Ockeloen CW, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. *Lancet Oncol.* 2011;12:49-55.
27. Barrow E, Alduaij W, Robinson L, et al. Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. *Clin Genet.* 2008;74:233-242.
28. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA.* 2011;305:2304-2310.
29. Choi YH, Cotterchio M, McKeown-Eyssen G, et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. *Hered Cancer Clin Pract.* 2009;7:14.
30. Dowty JG, Win AK, Buchanan DD, et al. Cancer risks for MLH1 and MSH2 mutation carriers. *Hum Mutat.* 2013;34:490-497.
31. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. *JAMA.* 2009;302:1790-1795.
32. Moller P, Seppala T, Bernstein I, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut.* 2015.
33. Ramsoek D, Wagner A, van Leerdam ME, et al. Cancer risk in MLH1, MSH2 and MSH6 mutation carriers; different risk profiles may influence clinical management. *Hered Cancer Clin Pract.* 2009;7:17.
34. Stoffel E, Mukherjee B, Raymond VM, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. *Gastroenterology.* 2009;137:1621-1627.
35. van der Post RS, Kiemeneij LA, Ligtenberg MJ, et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. *J Med Genet.* 2010;47:464-470.
36. Vasen HF, Stormorken A, Menko FH, et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. *J Clin Oncol.* 2001;19:4074-4080.
37. Baglietto L, Lindor NM, Dowty JG, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. *J Natl Cancer Inst.* 2010;102:193-201.
38. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. *Clin Genet.* 2009;75:141-149.
39. Hendriks YM, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. *Gastroenterology.* 2004;127:17-25.
40. Talseth-Palmer BA, McPhillips M, Groombridge C, et al. MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer. *Hered Cancer Clin Pract.* 2010;8:5.
41. Senter L, Clendenning M, Sotamaa K, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. *Gastroenterology.* 2008;135:419-428.
42. Burt R, Neklason DW. Genetic testing for inherited colon cancer. *Gastroenterology.* 2005;128:1696-1716.
43. Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. *Am J Gastroenterol.* 2015;110:223-262; quiz 263.
44. Aretz S, Genuardi M, Hes EJ. Clinical utility gene card for: MUTYH-associated polyposis (MAP), autosomal recessive colorectal adenomatous polyposis, multiple colorectal adenomas, multiple adenomatous polyps (MAP) - update 2012. *Eur J Hum Genet.* 2013;21.
45. Sampson JR, Jones N. MUTYH-associated polyposis. *Best Pract Res Clin Gastroenterol.* 2009;23:209-218.
46. De Brakeleer S, De Greve J, Loris R, et al. Cancer predisposing missense and protein truncating BARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. *Hum Mutat.* 2010;31:E1175-1185.
47. Palles C, Cazier JB, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. *Nat Genet.* 2013;45:136-144.
48. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nat Genet.* 2012;44:475-476; author reply 476.
49. Ricketts CJ, Forman JR, Rattenberry E, et al. Tumor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. *Hum Mutat.* 2010;31:41-51.
50. Frantzen C, Klasson TD, Links TP, Giles. Von Hippel-Lindau syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., eds. *GeneReviews®* [Internet]. Seattle, WA; Copyright, University of Washington, Seattle; 1993-2016. <http://www.ncbi.nlm.nih.gov/books/NBK1463/>. Updated August 6, 2015. Accessed May 25, 2016.
51. Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. *Eur J Hum Genet.* 2011;19:617-623.
52. Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. *Cancer Res.* 2000;60:6864-7.
53. Zhen DB, Rabe KG, Gallinger S, et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. *Genet Med.* 2014;17(7):569-577.
54. Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. *Human Molecular Genetics.* 2003;12(11):1241-1252.
55. Woodward ER, Ricketts C, Killick P, et al. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. *Clin Cancer Res.* 2008 Sep 15;14(18):5925-30.
56. Bartkova J, Tommiska J, Oplustilova L, et al. Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene. *Mol Oncol.* 2008 Dec;2(4):296-316.
57. Park DJ, Tao K, Le Calvez-Kelm F, et al. Rare mutations in RINT1 predispose carriers to breast and Lynch syndrome-spectrum cancers. *Cancer Discov.* 2014 Jul;4(7):804-15.
58. Cao Z, Song JH, Kang YW, et al. Analysis of succinate dehydrogenase subunit B gene alterations in gastric cancers. *Pathol Int.* 2010 Aug;60(8):559-65.
59. Park DJ, Lesueur F, Nguyen-Dumont T, et al. Rare Mutations in XRCC2 Increase the Risk of Breast Cancer. *Am J Hum Genet.* 2012 Apr 6;90(4):734-9.
60. Ramus SJ, Song H, Dicks E, et al. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *J Natl Cancer Inst.* 2015 Aug 27;107(11).
61. Seal S, Thompson D, Renwick A, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat Genet.* 2006 Nov;38(11):1239-41.
62. Tirosh A, Sadowski SM, Linehan WM, et al. Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. *JAMA Oncology* 2018 Jan 01;4(1):124-126.

Millennium Health contracts with Kailos Genetics

to provide patients with Millennium HCR.

Learn more at millenniumHCR.com

